Clinical and biochemical correlates of 'high-dose' clozapine therapy for treatment - Refractory schizophrenia [2]

Peter F Buckley; A. C. Krowinski; D. D. Miller; L. Friedman; Y. Eaton; M. Tronetti

doi:10.1016/S0920-9964(99)00084-5

Clinical and biochemical correlates of 'high-dose' clozapine therapy for treatment - Refractory schizophrenia [2]

Peter F Buckley, A. C. Krowinski, D. D. Miller, L. Friedman, Y. Eaton, M. Tronetti

Graduate Studies

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	225-227
Number of pages	3
Journal	Schizophrenia Research
Volume	49
Issue number	1-2
DOIs	https://doi.org/10.1016/S0920-9964(99)00084-5
State	Published - Apr 15 2001

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0920-9964(99)00084-5

Cite this

@article{f0d22ce52cd346f194b9f075d39e8c35,

title = "Clinical and biochemical correlates of 'high-dose' clozapine therapy for treatment - Refractory schizophrenia [2]",

author = "Buckley, {Peter F} and Krowinski, {A. C.} and Miller, {D. D.} and L. Friedman and Y. Eaton and M. Tronetti",

note = "Funding Information: This work was supported in part by a grant from Novartis Pharmaceuticals Corporation. The secretarial assistance of Ms Andrea J. Miles is greatly appreciated. We are also grateful to Craig Richman, MD, Penny Chapman, MD, John Evans, Lee Penman, and Michelle Donovic, through Cll, Erie, for their assistance and support of this project.",

year = "2001",

month = apr,

day = "15",

doi = "10.1016/S0920-9964(99)00084-5",

language = "English (US)",

volume = "49",

pages = "225--227",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Clinical and biochemical correlates of 'high-dose' clozapine therapy for treatment - Refractory schizophrenia [2]

AU - Buckley, Peter F

AU - Krowinski, A. C.

AU - Miller, D. D.

AU - Friedman, L.

AU - Eaton, Y.

AU - Tronetti, M.

N1 - Funding Information: This work was supported in part by a grant from Novartis Pharmaceuticals Corporation. The secretarial assistance of Ms Andrea J. Miles is greatly appreciated. We are also grateful to Craig Richman, MD, Penny Chapman, MD, John Evans, Lee Penman, and Michelle Donovic, through Cll, Erie, for their assistance and support of this project.

PY - 2001/4/15

Y1 - 2001/4/15

UR - http://www.scopus.com/inward/record.url?scp=0035871091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035871091&partnerID=8YFLogxK

U2 - 10.1016/S0920-9964(99)00084-5

DO - 10.1016/S0920-9964(99)00084-5

M3 - Letter

C2 - 11428347

AN - SCOPUS:0035871091

SN - 0920-9964

VL - 49

SP - 225

EP - 227

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1-2

ER -

Clinical and biochemical correlates of 'high-dose' clozapine therapy for treatment - Refractory schizophrenia [2]

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this